GT BIOPHARMA, INC. Cost of Revenue
GT BIOPHARMA, INC. (GTBP) reported Cost of Revenue of $0 for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-15.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2020-05-15
- GT BIOPHARMA, INC. cost of revenue for the quarter ending 2020-03-31 was $0.00.
- GT BIOPHARMA, INC. cost of revenue for the quarter ending 2019-03-31 was $0.00.
- GT BIOPHARMA, INC. cost of revenue for the quarter ending 2018-03-31 was $0.00.
| Period end | Cost of Revenue 3 month |
|---|---|
| 2020-03-31 | $0.00 10-Q · filed 2020-05-15 |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-15 |
| 2018-03-31 | $0.00 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |